Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
 - EconoTimes)
NEW YORK, Jan. 26, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against HeartWare International, Inc. (“Heartware” or the “Company”) (Nasdaq:HTWR) in the United States District Court for the Southern District of New York on behalf of a class consisting of all persons or entities who purchased HeartWare securities between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the Company and certain of its senior executives violated provisions of the Exchange Act by making numerous false and misleading statements and omissions of material fact, including in press releases and in statements during conferences and conference calls with analysts and investors. Specifically, the Complaint alleges that after the U.S. Food and Drug Administration (“FDA”) issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that they therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
